LH eyes growth via specialty test expansion, acquisitions and LaunchPad savings, but currency headwinds and macro pressures cloud the outlook.

If you are wondering whether Labcorp Holdings is priced attractively right now, starting with a clear look at its valuation can help you decide how it fits into your portfolio. The stock recently ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know. Labcorp met analysts’ revenue ...

Laboratory Corp (NYSE: LH) reported third-quarter 2025 adjusted earnings per share of $4.18 on Tuesday, up from $3.50 a year ago, beating the consensus of $4.18. Sales increased 8.6% year-over-year to ...

(LH) on Tuesday reported fourth-quarter profit of $164.7 million. The Burlington, North Carolina-based company said it had ...

Feb 6 (Reuters) - Labcorp (LH.N), opens new tab forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx 1, an FDA-cleared digital pathology ...

Labcorp expanded its partnership with PathAI to offer its FDA-cleared digital pathology platform at the life science giant’s U.S. network of anatomical pathology labs and participating hospitals.